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Introduction 28 
In addition to obesity, T2DM is a major risk factor for cardiovascular disease (CVD). Hyperglycemia 29 
and insulin resistance (IR) are powerful predictors of adverse cardiovascular events, and these two 30 
risk factors in combination exert a detrimental synergistic effect [1]. However, despite a number of 31 
recognized risk factors including family history of diabetes, age, sex, and numerous anthropometric, 32 
biochemical, socioeconomic, and lifestyle variables, the identification of individuals with increased 33 
risk of T2DM and/or CVD remains a laborious task [2]. Typical biomarkers in T2DM prediction 34 
models include elevated concentrations of fasting plasma glucose and insulin, glycated hemoglobin 35 
(HbA1c), serum ferritin, C-reactive protein (CRP), and interleukin-2 receptor alpha (IL2RA); these 36 
models also predict a decrease in effective serum insulin and adiponectin concentrations [3, 4]. 37 
Recent advances in “omics” such as genomics and metabolomic technologies are generating an 38 
increasing number of potential biomarkers to identify crucial stages in the pathogenesis and 39 
progression of a determined pathological state, including T2DM. In addition, they are also gaining 40 
insights in the underlying molecular disease-causing mechanisms through the discovery of 41 
associations between some genetic variants and key small molecules. These relationships highlight 42 
the power of integrating multiomic approaches (Systeomics) to better understand the causal 43 
mechanisms [5]. For instance, recently, Wang et al. [6] delineated the role of fatty acid desaturases 44 
(FADs) in regulating human liver lipid composition through a targeted lipidomic analysis and 45 
associated them with FADS single nucleotide polymorphisms (SNPs) from genome-wide association 46 
studies (GWASs). They suggested that FADS1 and its polymorphisms were related with long-chain 47 
fatty acid accumulation in human liver [6]. Metabolomics is defined as a comprehensive 48 
characterization of endogenous or exogenous metabolites representing the metabolome [7]; the use 49 
of this technology enables the detection of physiological or pathological changes in cells, tissues, or 50 
body fluids and represents a useful tool for biomarker detection [8, 9]. In diabetes research, 51 
metabolomics has been successfully applied to diagnostic and prognostic biomarker discovery, 52 
elucidation of disease pathways, identification of drug side effects, and discovery of functional 53 
biomarkers for drug activity [10]. The present review aims to summarize the distinct family of 54 
metabolites that have been proposed as potential biomarkers of different stages of T2DM by 55 
metabolomic approaches. Additionally, the impact of diet, as an important lifestyle factor, on classical 56 
and metabolomic biomarkers will be reviewed for better understanding the pathophysiology of 57 
diabetes, aiming to implement healthcare strategies in the future. 58 
Metabolomic Biomarkers in Prediabetes 59 
The term prediabetes refers to the impaired glucose tolerance (IGT) and/or impaired fasting glucose 60 
(IFG) of subjects with a relatively high risk of developing diabetes. IFG is characterized by fasting 61 
plasma glucose levels between 100 mg/dl (5.6 mmol/l) and 126 mg/dl (7.0 mmol/l). IGT is defined 62 
by 2-h plasma glucose values after an oral glucose tolerance test (OGTT); values between 140 mg/dl 63 
(7.8 mmol/l) and 200 mg/ dl (11.1 mmol/l) are considered indicative of IGT [11]. In addition to IFG 64 
and IGT, IR is also considered a crucial metabolic status because it can precede the dysglycemic 65 
states of prediabetes and T2DM [12]. Because prediabetic stages are asymptomatic, extended time 66 
periods may elapse before diagnosis of T2DM, hampering early detection. In addition to the most 67 
common test used to assess impaired insulin sensitivity (IS), homeostasis model assessment of insulin 68 
resistance (HOMA-IR), OGTTs are also indirectly used to assess insulin resistance.  69 
Metabolomics may be extremely helpful in the identification of novel biomarkers of prediabetes and 70 
metabolic disturbances that precede the new onset of T2DM. In this regard, a targeted metabolomic 71 
approach has shown that IR emerges in insulin-dependent processes, such as proteolysis, lipolysis, 72 
ketogenesis, and glycolysis, in addition to the reduction in glucose uptake and suppression of 73 
gluconeogenesis, thus, reflecting a broad switch from catabolism to anabolism [13]. The 74 
understanding of the role of dyslipidemia in prediabetes has progressed significantly with the 75 
implementation of lipidomics, a new branch of metabolomics [14–16]. The current and advanced 76 
analytical techniques used in lipidomics such as chromatography coupled to mass spectrometry (MS) 77 
or nuclear magnetic resonance (NMR) as well as other spectroscopic approaches are powerful 78 
techniques used in lipidomics for lipid detection and characterization [17]. They allow detection and 79 
characterization up to several hundreds of lipids belonging to major lipid classes (i.e., fatty acyls, 80 
phospholipids, glycerolipids, glycerophospholipids, sphingolipids, sterol lipids) [17]. As an example 81 
of the high throughput obtained by these technologies, a recent lipidomic study reported over 500 82 
different lipid molecular species among the main lipid classes in plasma of individuals [18]. The 83 
importance of lipoprotein fatty acid composition and its role in IS has been emphasized in a study 84 
using lipidomic techniques, including ultra-performance liquid chromatography coupled to mass 85 
spectrometry (UPLC/MS). In this study, the degree of fatty acid saturation in triacylglycerols (TAG) 86 
within the VLDLIDL- LDL axis and HDL were differentially related to IR [15]. Specifically, serum 87 
TAG molecules, such as 16:0/16:0/18:1 and 16:0/18:1/18:0, correlated positively with HOMA-IR; 88 
however, TAG containing essential fatty acids, such as 18:1/ 18:2/18:2, correlated negatively. The 89 
findings of this study reinforce the role that fatty acids may have in the pathogenesis of IR; therefore, 90 
the serum fatty acid composition may be considered a more precise marker of insulin resistance than 91 
total serum TAG concentrations [15]. Consistent with this hypothesis, in the Framingham Heart Study 92 
(FHS), serum TAG characterized by relatively low carbon number and double bond content (i.e., 93 
C46:1, 48:1) were positively associated with HOMA-IR; conversely, TAG with increased carbon 94 
number and double bond content (i.e., C56:9, C58:10) were not correlated with HOMA-IR [16]. 95 
These results were consistent even after the participants were grouped in quartiles according to 96 
HOMA-IR [16].  97 
Zhao et al. [19] also observed a characteristic lipid profile for individuals with IGT as a prediabetic 98 
condition. Applying untargeted metabolomics using UPLC-qTOF-MS, the authors reported increased 99 
plasma levels of free fatty acids (FFA) (i.e., C16:0, C18:0, C18:1) and glycochenodeoxycholic acid 100 
as well as decreased concentrations of lysophosphatidylcholines (lysoPC) (i.e., C16:0, C18:0, C18:1 101 
and C18:2) relative to subjects with normal glucose tolerance (NGT) [19]. In the same study, the 102 
NGT individuals trended towards lower plasma levels of saturated fatty acids (SFA), including 103 
palmitate and stearate, but not monounsaturated (MUFA) or polysaturated fatty acids (PUFA), such 104 
as oleate and arachidonic acid, respectively [19]. 105 
Beyond the isolated impact of dyslipidemia, amino acid signature has been also reported as a 106 
characteristic signature in obese prediabetic subjects. In a broad metabolic profiling study performed 107 
by Newgard et al., the PCA-component including certain amino acids, branched-chain amino acids 108 
(BCAA) (leucine/isoleucine and valine), methionine, glutamate/ glutamine, aromatic amino acids 109 
(phenylalanine and tyrosine), as well as acylcarnitines (AcylCN) C3 and C5 was obesity associated 110 
and linearly related to IR assessed by the HOMA index [20]. These findings were supported by 111 
Huffman et al., who reported that a similar group of metabolites containing large neutral amino acids 112 
(proline, valine, leucine/ isoleucine, methionine, phenylalanine, tyrosine, histidine) and uric acid were 113 
related to IR in a mixed-sex population (n=73) at risk for T2DM [21]. Additionally, a group of 114 
metabolites including FFA and fatty acid oxidation byproducts was associated with an impaired 115 
pancreatic response. The authors suggested that a poor compensatory response to insulin production 116 
is associated with increased concentrations of circulating FFA, potentially having a toxic effect on β 117 
cells in prediabetic subjects [21]. Interestingly, the same authors also observed sex differences; men 118 
were more susceptible to amino acid-induced IR, whereas women were more vulnerable to lipid-119 
mediated β cell toxicity [21]. More recently, using proton nuclear magnetic resonance (1HNMR)- 120 
based analysis, a set of 20 serum metabolites was also associated with IR in a cohort of 7098 young 121 
adults [22]. 122 
BCAAs, aromatic amino acids, glycolysis and gluconeogenesis intermediates, and fatty acid 123 
composition and saturation were positively correlated with HOMA-IR. Conversely, glutamine and 124 
ketone bodies (3-hydroxybutyrate and acetoacetate) exhibited an inverse correlation, as did the 125 
average number of double bonds per fatty acid chain. Furthermore, the authors observed interactions 126 
between four amino acids (leucine, isoleucine, valine, and tyrosine) and sex and obesity variables, 127 
with significant associations in women with central obesity [22]. Nevertheless, the ethnicity of 128 
populations has to take into account when interpreting results. Metabolomics [23], jointly with 129 
genomics [24], is a promising and needed tool for evaluating differences between different ethnical 130 
populations as previously some studies observed that different populations have different rates of 131 
T2DM [24]. A recent metabolomic study has shown that a pattern of reduced plasma glycine and 132 
increased aromatic and BCAA was related to individuals with high IS compared with low IS 133 
individuals in European-American subjects, while other ethnics (Hispanics or African Americans) 134 
did not show the same associations [23]. Further metabolomic studies are needed in ethnically and 135 
racially diverse populations. To segregate the effects of obesity and IR on the metabolic changes 136 
observed in prediabetic subjects, Tai et al. compared the metabolic profiling of two non-obese (BMI 137 
~24 kg/m2) Asianethnic populations with IR. Using a combination of two metabolic platforms, 138 
tandem mass spectrometry (MS/MS), and gas chromatography coupled toMS (GC-MS), the authors 139 
identified significant changes in plasma and urine metabolites in individuals separated by tertiles of 140 
IR based on HOMA indices [25]. The results showed up to 26 clusters composed of amino acid and 141 
AcylCN, between other metabolites that contributed to the grade of IR. One of these clusters was 142 
composed of 10 amino acids that were significantly increased in individuals with a high HOMA 143 
index. The same trend was observed in another group composed of pyruvate, lactate, and arginine. 144 
Moreover, isobutyrylglycine and isovalerylglycine , included in another cluster, were significantly 145 
lower in the high-HOMA group than in the low-HOMA group but in only one population. 146 
Interestingly, no association between IR and traditional IR biomarkers such as inflammatory 147 
mediators and fatty acids was observed in this study [25]. 148 
Metabolic signatures of prediabetes composed of few metabolites have been proposed in several 149 
studies. Wang-Sattler et al. quantified 140 metabolites with an AbsoluteIDQTM p180 kit 150 
(BIOCRATES Life SciencesAG, Innsbruck, Austria) in fasting serum samples of subjects from the 151 
Cooperative Health Research in the KORA S4 study. The authors observed that glycine and lysoPC 152 
18:2 were significantly decreased, whereas AcylCN C2 was increased in IGT individuals compared 153 
to the NGT group [26•]. Similar results were observed in the follow-up KORA F4 study. In the 154 
prospective KORA S4→F4 cohort, lower levels of glycine and lysoPC 18:2, but not C2 AcylCN, 155 
were found to be predictors of both IGT and T2DM. This was independently confirmed by the same 156 
authors in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort 157 
[26•]. In other clinical studies, α-hydroxybutyrate (α-HB) has also been proposed as a strong 158 
prediabetic biomarker [27, 28•]. Based on a subset (n=399) of the EPIC cohort, Gall et al. identified 159 
α-HB as the most significant metabolite associated with IR and, interestingly, as an early marker for 160 
dysglycemia (IFG + IGT) independent of and in addition to IR [27]. Ferrannini et al. later confirmed 161 
the association of α-HB with IR, along with the novel metabolite linoleoylglycerophosphocholine (L-162 
GPC) [28•]. Ferranini et al. observed a positive correlation between α-HB and IR in two prospective 163 
observational cohorts, the Relationship between Insulin Sensitivity and Cardiovascular Disease 164 
(RISC) study (n=1261) and the Botnia Prospective Study (n=2580) with 3 and 9.5 years of follow-165 
up, respectively. Additionally, L-GPC was negatively correlated with IR. α- HB was also reciprocally 166 
related to indices of β cell function derived from OGTT. In the follow-up of both studies, α-HB was 167 
a positive predictor and L-GPC a negative predictor of dysglycemia (RISC study) or T2DM(Botnia 168 
Study), independently of the family history of diabetes, sex, age, BMI, and fasting plasma glucose 169 
[27]. Recently, a novel branched-chain ketoacid derivative of isoleucine, called 3-methyl-2- 170 
oxovalerate, was found to be significantly associated to IFG, both in the plasma and urine of 171 
individuals with prediabetes relative to control individuals with diabetes [29]. The observation that 172 
3-methyl-2-oxovalerate was the second strongest predictive biomarker for IFG, after glucose, was 173 
first reported in a cohort of 2204 females from Twins, UK, and was subsequently replicated in 174 
individuals with IFG (n=536) in the follow-up study KORA F4 [29]. Other metabolites that are not 175 
directly linked with major metabolic pathways have been significantly associated with prediabetes. 176 
For example, decreased urinary levels of gut microbiota-associated metabolite biomarkers, including 177 
hippuric acid, methylxanthine, methyluric acid, and 3- hydroxyhippuric acid, have been linked to 178 
IGT [19].  179 
Metabolomics Biomarkers and Pathways Altered in T2DM 180 
Because T2DM triggers multiple metabolic disorders, efforts have been made to elucidate the 181 
mechanisms causing these disorders and systemic complications. Metabolomics has been 182 
successfully applied in T2DM research to elucidate novel metabolic pathways as well as to define 183 
relationships between significant metabolites in these pathways. Nowadays, the knowledge of 184 
interactions between affected T2DM pathways is improving through building biological pathways 185 
and network analysis techniques which integrate data from the different Bomics^ [30, 31]. To obtain 186 
a more comprehensive analysis of the metabolic processes negatively regulated by T2DM, a summary 187 
of metabolomic studies and the resulting metabolites significantly altered in diabetics is shown in 188 
Table 1. Furthermore, Fig. 1 illustrates a summary of metabolic networks presumably affected by 189 
T2DM. To this end, we used the MetaCoreTM software (Thomson Reuters) fromGeneGo, uploading 190 
the complete list of T2DM biomarkers reported in literature (Table 1). Metabolomic studies 191 
evaluating individuals with T2DM confirm that metabolic networks of primary biomolecules, such 192 
as carbohydrates, lipids, and amino acids, are altered as a consequence of the diabetic stage (Fig. 1). 193 
Hyperglycemia and glycosuria are the major biomarkers of uncontrolled T2DM [29, 54]. However, 194 
abnormal levels of other metabolites reflect dysregulation of carbohydrate metabolism (i.e., fructose, 195 
mannose) (Fig. 1). Impairment of glycolysis and gluconeogenesis has been demonstrated by 196 
metabolomic approaches through the identification of metabolites included in the sepathways: 197 
glycerol-3-phosphate, phosphoenolpyruvate, pyruvate, and lactate. Additionally, downstream 198 
tricarboxylic acid cycle (TCA) metabolites, such as citrate, 2-oxoglutarate, succinate, fumarate, and 199 
malate, are deregulated in diabetes (Table 1). Controversial results suggest that levels of circulating 200 
and urinary glucogenic amino acids [29, 33, 36, 39, 41, 45, 46, 52, 55] in diabetic subjects indicate 201 
deregulation of glucose biosynthesis (Table 1). Furthermore, significant increases in three ketone 202 
bodies, acetone, acetoacetate, and β-hydroxybutyrate, in plasma [32, 41] and urine [34], reflect a 203 
reduction in glucose uptake and the onset of ketosis in T2DM [56]. A considerable number 204 
ofmetabolomic studies have reported a positive association between abnormal circulating 205 
concentrations of lipid derivatives and T2DM progression. Although not necessarily consistent with 206 
prediabetes with respect to saturation, higher concentrations of long-chain (i.e., oleic, palmitic) and 207 
lower concentrations of medium-chain FFAs (i.e., caproate, pelargonate, 10-undecenoate) are a 208 
characteristic lipid signature among individuals with T2DM [41, 43, 45, 57]. Using GC-MS analysis, 209 
Han et al. demonstrated that primarily esterified fatty acids (EFA) are decreased in patients with 210 
T2DM, while non-esterified fatty acids (NEFA) are increased. This occurs even when including the 211 
variability of groups with different stages of diabetic nephropathy, suggesting a combination of 212 
lipotoxicity and toxicology repair mechanism [47]. Applying a lipidomic approach, Ståhlman et al. 213 
characterized the lipid composition of ApoB-containing lipoproteins isolated from control, 214 
normolipidemic, and dyslipidemic individuals with T2DM [58]. Significant increases in PC 16:0-215 
20:3 (in VLDL and LDL) and PC 18:0-20:3 (in LDL) were detected in normolipidemic T2DM 216 
compared with control individuals. These alterationsweremore pronounced in the dyslipidemic 217 
T2DM group, which also had a relatively increased amount of PC 16:0-16:1. Similarly, significant 218 
increases in CE 16:1 (in VLDL and LDL) and CE 20:3 (in LDL) were detected in lipoproteins from 219 
dyslipidemic T2DM participants. Furthermore, levels of palmitic acid (C16:0) in VLDL and LDL 220 
TAG correlated positively with IR [58]. Abnormal circulating levels of distinct subclasses of 221 
phospholipids, including PC, lysoPC, phosphatidylinositol (PI), PE, lysoPE, SM, PG, and 222 
sphingosine-1-phosphate (Table 1), have also been identified bymetabolomic approaches and were 223 
considered potential biomarkers of the diabetic dyslipidemia [48, 49, 53]. Ceramides, another 224 
important class of bioactive lipids, have recently garnered attention due their pathophysiological 225 
relevance in the development of IR and impaired glycemic control [59]; therefore, ceramide 226 
concentrations are significantly deregulated in T2DM [37]. A research focused on acylcarnitines 227 
(AcylCN) and their byproducts has generated insights into the dysregulation of fatty acid oxidation 228 
associated with T2DM. Variations in the levels of AcylCN, mostly from short to medium chains, 229 
have been detected by applying targeted metabolomic analyses to T2DM before its onset, there is 230 
great demand for reliable, predictive biomarkers. Targeted metabolomic studies have increasingly 231 
aided in the development of novel biomarkers in large prospective studies [16, 60••, 61, 62]. 232 
Consistent with previous observations in individuals with IR, Rhee et al. observed a characteristic 233 
association between carbon number and bond content that was predictive of developing T2DM. 234 
Specifically, TAG with a lower carbon number and double bond content were associated with an 235 
increased odds ratio (OR) for diabetic subjects, while TAG with a higher carbon number and double 236 
bond content were associated with an OR of less than one. Moreover, the inverse relationship between 237 
diabetes risk, carbon number, and double bond content persisted after multivariable adjustment for 238 
lysoPC, PC, and possibly lysophosphatidylethanolamines (lysoPE), but not for cholesterol esters 239 
(CE) [16]. In another but complementary study, Wang et al. carried out two parallel and independent 240 
studies based on the same sample population. These authors discovered two novel metabolic 241 
signatures for the prediction of T2DM [60••, 62]. In the first study, higher levels in a panel of five 242 
amino acids (isoleucine, leucine, phenylalanine, tyrosine, and valine) showed a strong association 243 
with future development of diabetes. Moreover, a combination of three amino acids (isoleucine, 244 
tyrosine, and phenylalanine) was shown to be a better predictor of future diabetes than all five amino 245 
acids; individuals in the top quartile of this 3-amino acid score had a five- to sevenfold higher risk of 246 
developing new-onset diabetes compared with individuals in the lowest quartile [60••]. These results, 247 
with the exception of a nonsignificance of isoleucine, were replicated by the same authors in the 248 
Malmö Diet and Cancer (MDC) study [60••]. Later, Wang et al. reported that the odds of developing 249 
T2DM were increased fourfold for individuals in the higher quartile of plasma 2-aminoadipic acid 250 
(2-AAA) concentrations over the 12-year follow-up period, relative to those in the lowest quartile. 251 
These results were replicated in the MDC study and were confirmed in a heterogeneous cohort from 252 
the FHS-Offspring study (n=1561) [62]. Additionally, fasting concentrations of 2- AAAwere 253 
moderately correlated with fasting insulin, HOMAIR, HOMA of β cell function, and OGTT. 254 
However, concentrations of 2-AAA were poorly correlated with the previous set of five amino acids 255 
associated with future diabetes risk, suggesting that these biomarkers are regulated by distinct 256 
pathophysiological pathways [62]. More recently, Floegel et al. confirmed that dysfunctional levels 257 
of lipid-related metabolites and amino acids are potent biomarkers for future T2DM prediction [61]. 258 
In the EPIC-Potsdam study, researchers identified 14 metabolites that were independently and 259 
significantly associated with T2DM risk. They used a PCA to identify 2 factors which included 260 
different metabolites. Metabolite factor 1, consisting of primarily acyl-alkyl-PCs, sphingomyelins 261 
(SM), and lysoPC, was associated with a significant 69 % reduced risk of T2DM when comparing 262 
extreme quintiles of metabolite factors. Conversely, metabolite factor 2, consisting of diacyl- PCs, 263 
BCAA and aromatic amino acids, propionylcarnitine, and hexose, was associated with a significantly 264 
greater risk of T2DM. Remarkably, when these metabolites were added to classical models using 265 
recognized risk factors of T2DM, discrimination was slightly but significantly improved [61].  266 
Nutritional Interventions in Metabolomics Biomarkers of T2DM Pharmacological and lifestyle 267 
interventions have a significant impact on T2DMpatients [63]. Among lifestyle factors, diet is a 268 
strong modulator of health status [64]. Diets rich in whole grains, fruits, vegetables, legumes, and 269 
nuts combined with moderate consumption of alcohol and lower in refined grains, red or processed 270 
meats, and sugar-sweetened beverages have been shown to reduce the risk of diabetes and also 271 
improve glycemic control and blood lipids in patients with diabetes [65••, 66, 67]. A recent systematic 272 
review and meta-analysis of dietary T2DM management approaches has highlighted that low-273 
carbohydrate, low-glycemic index (GI), Mediterranean (MedDiet), and high-protein diets effectively 274 
improve various markers of cardiovascular risk [68]. These diets successfully reduced HbA1c, 275 
stimulated weight loss, and increased HDL concentrations in people with diabetes. These studies 276 
suggest that dietary patterns should be considered in the overall strategy of diabetes management 277 
[68]. The MedDiet has received particular attention due to its demonstrated efficacy in preventing 278 
CVD [69••], in addition to its association with reduced incidence of metabolic syndrome, prediabetes 279 
[70], and T2DM [71]. Salas-Salvadó et al. recently showed a positive effect of MedDiet on T2DM 280 
prevention, comparing two types of MedDiet and using a low-fat diet as a control in subjects with 281 
high CVD risk [72, 73]. In an interventional study, the authors discovered that without energy 282 
restrictions, MedDiet enriched with either extra-virgin olive oil (EVOO) or mixed nuts reduced the 283 
risk of T2DM [72]. By assessing the efficacy of long-term adherence to MedDiet (median follow-up, 284 
4.1 years), the authors found that the EVOO MedDiet group exhibited a lower incidence of T2DM 285 
compared to the nut-enriched MedDiet or control diet [73]. In 2011, several diet-quality scores 286 
(Healthy Eating Index [HEI], the alternative HEI [aHEI], the alternative Mediterranean Diet (aMED), 287 
and the Dietary Approaches to Stop Hypertension [DASH]) were studied to be associated with 288 
incident T2DM in the Health Professionals Follow-Up Study [66]. They observed that three scores 289 
(aHEI, aMED, and DASH) were significantly related with a decreased risk of T2DM[66]. Recently, 290 
the BInterAct Consortium studied the association between aHEI and DASH scores and three reduced 291 
rank regression (RRR)-derived dietary pattern scores from different studies (the American Nurses’ 292 
Health Study, German EPICPotsdam study, and the British Whitehall II study, respectively) with 293 
T2DM^ [67]. Only adherence to these RRR-derived dietary pattern scores decreased type 2 diabetes 294 
risk in the EPIC-InterAct Study [67]. It is noteworthy to comment that adherence to these scores were 295 
represented by high intake of plant-derived foods and low intake of red and processed meat and sugar-296 
sweetened beverages [66, 67]. In this line, alkylresorcinol has been described as a valid biomarker 297 
for a Nordic diet (ND) which is rich in whole-grain cereals [74]. The alkylresorcinol C17:0/C21:0 298 
ratio has been inversely related with increased IS [75]. There has been moderate-grade evidence that 299 
the intake of whole-grains protected against T2DM [76]. Otherwise, further studies are required for 300 
examining associations between ND and its characteristic foods and T2DM [76, 77]. In recent years, 301 
metabolomics has been widely applied to interventional studies to identify variations in human 302 
metabolic profiling in response to food [78–83]; however, this approach has rarely been applied to 303 
the assessment of the effect of foods on particular pathologic states [84–86]. For instance, regular 304 
consumption of cocoa powder decreased the levels of endogenous metabolites related tometabolic 305 
disorders, such as carnitine metabolites and tyrosine sulfate [86]. However, the impact of dietary 306 
interventions such as MedDiet on the metabolome of T2DM subjects has not been well characterized. 307 
Future studies are warranted to develop novel biomarkers in response to diet challenges. This could 308 
establish appropriate dietary therapeutic strategies to improve the life course of T2DM patients. 309 
Conclusions 310 
Metabolomics is a rapidly growing field to identify novel biomarkers for different stages of T2DM. 311 
In the face of the current diabetes epidemic, future research should consider the relevance of novel 312 
biomarkers for the prediction and diagnosis of T2DM and the elucidation of disease pathways 313 
implicated in this disease. Metabolomic approaches have identified distinct classes of metabolites as 314 
potential biomarkers for different stages of T2DM. Several studies have demonstrated that the 315 
metabolism of carbohydrates, lipids, and amino acids are considerably altered in the prediabetic state 316 
and at different stages of T2DM progression. The identification of intermediate metabolites included 317 
in glycolysis, gluconeogenesis, the tricarboxylic acid cycle, lipolysis, and proteolysis have provided 318 
evidence for this metabolic dysfunction. Due to the scarcity of information on the effects of lifestyle 319 
changes on metabolomic biomarkers, more effort should be directed in expanding our knowledge to 320 
the metabolic modulations caused by dietary patterns in T2DM patients. Lifestyle interventions have 321 
a significant impact on diabetes prevention and control through modeling peripheral classical 322 
biomarkers of T2DM; therefore, future studies should aim to develop novel biomarkers that are 323 
sensitive to food challenge. This could establish appropriate dietary strategies to help improve the 324 
life course of T2DM patients. 325 
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FIGURES 584 
 585 
Fig. 1 Summary of metabolic networks affected in T2DM according to the presence of metabolites 586 
in urine (top orange bar) and serum/plasma (lower blue bar)*. *Networks listed were obtained by an 587 
Enrichment Analysis inMetaCoreTM (Genego, St. Joseph, MI) and ordered according to the major 588 
metabolic pathways involved. Figure includes metabolites listed in Table 1 separated by urine and 589 
serum/plasma and their direction. A figure with the full list of metabolic networks resulting from 590 
MetaCoreTM is available in the supplementary material 591 
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